Depreciation of Aquestive Therapeutics, Inc. from 31 Mar 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Aquestive Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Mar 2018 to 31 Dec 2025.
  • Aquestive Therapeutics, Inc. Depreciation for the quarter ending 31 Dec 2025 was $130,000, a 12% decline year-over-year.
  • Aquestive Therapeutics, Inc. Depreciation for the twelve months ending 31 Dec 2025 was $548,000, a 14% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2025 was $548,000, a 14% decline from 2024.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2024 was $640,000, a 44% decline from 2023.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2023 was $1,153,000, a 49% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Aquestive Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $548,000 $130,000 -$18,000 -12% 01 Oct 2025 31 Dec 2025 10-K 04 Mar 2026 2025 FY
Q3 2025 $566,000 $139,000 -$20,000 -13% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $586,000 $140,000 -$25,000 -15% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $611,000 $139,000 -$29,000 -17% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $640,000 $148,000 -$251,000 -63% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2026 2025 FY
Q3 2024 $891,000 $159,000 -$59,000 -27% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $950,000 $165,000 -$85,000 -34% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $1,035,000 $168,000 -$118,000 -41% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $1,153,000 $399,000 +$55,000 +16% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 $1,098,000 $218,000 -$339,000 -61% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $1,437,000 $250,000 -$405,000 -62% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $1,842,000 $286,000 -$428,000 -60% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $2,270,000 $344,000 -$373,000 -52% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $2,643,000 $557,000 -$167,000 -23% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $2,810,000 $655,000 -$73,000 -10% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $2,883,000 $714,000 -$29,000 -3.9% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $2,912,000 $717,000 -$547,000 -43% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $3,459,000 $724,000 +$10,000 +1.4% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $3,449,000 $728,000 +$28,000 +4% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $3,421,000 $743,000 +$29,000 +4.1% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $3,392,000 $1,264,000 +$552,000 +78% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $2,840,000 $714,000 +$19,000 +2.7% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $2,821,000 $700,000 -$11,000 -1.5% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $2,832,000 $714,000 -$22,000 -3% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $2,854,000 $712,000 -$36,000 -4.8% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $2,890,000 $695,000 -$38,000 -5.2% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $2,928,000 $711,000 -$54,000 -7.1% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $2,982,000 $736,000 -$204,000 -22% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $3,186,000 $748,000 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $733,000 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $765,000 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $940,000 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1

Aquestive Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $548,000 -$92,000 -14% 01 Jan 2025 31 Dec 2025 10-K 04 Mar 2026 2025 FY
2024 $640,000 -$513,000 -44% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2026 2025 FY
2023 $1,153,000 -$1,117,000 -49% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
2022 $2,270,000 -$642,000 -22% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $2,912,000 -$480,000 -14% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $3,392,000 +$538,000 +19% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $2,854,000 -$332,000 -10% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $3,186,000 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.